Multiple chemical sensitivity described in the Danish general population: Cohort characteristics and the importance of screening for functional somatic syndrome comorbidity—The DanFunD study

Thomas Meinertz Dantoft¹*, Steven Nordin², Linus Andersson³, Marie Weinreich Petersen⁴, Sine Skovbjerg⁴, Torben Jørgensen¹,⁵,⁶

¹ Center for Clinical Research and Prevention, Bispebjerg & Frederiksberg Hospital, Frederiksberg, Capital Region Denmark, ² Department of Psychology, Umeå University, Umeå, Sweden, ³ The Research Clinic for Functional Disorders and Psychosomatics, Aarhus University Hospital, Aarhus, Denmark, ⁴ Department of Clinical Medicine, Danish Center for Mindfulness, Aarhus University, Aarhus, Denmark, ⁵ Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁶ Faculty of Medicine, Aalborg University, Aalborg, Denmark

* thomas.meinertz.dantoft@regionh.dk

Abstract

Background

Multiple chemical sensitivity (MCS) is characterized by widespread symptoms attributed to exposure to airborne chemicals. MCS is categorized as a functional somatic syndrome (FSS), and MCS cases often meet the criteria for other types of FSS, e.g. fibromyalgia. The primary aim was to characterize MCS regarding symptom triggers, symptoms, lifestyle and describe demographics, socioeconomics and lifestyle factors associated with MCS. A secondary aim was to examine the implication of FSS comorbidity.

Methods

Data were derived from a random sample of the Danish adult population enrolled in the Danish Study of Functional Disorders (DanFunD; n = 9,656). Questionnaire data comprised information used to delimit MCS and four additional types of FSS, as well as data on demographics, socioeconomics and lifestyle. MCS cases (n = 188) was stratified into subgroups; MCS only (n = 109) and MCS with comorbid FSS (n = 73). Information regarding FSS comorbidities were missing for six MCS cases. MCS subgroups and controls without FSS comorbidities (n = 7,791) were compared by means of logistic regression analyses, adjusted for age and sex.

Results

MCS was associated with female sex, not being in occupation and low social status, but not with age or education. MCS cases reported normal dietary intake and smoking habits and
lower alcohol consumption. Additional associations were found between MCS and low rate of cohabitation, sedentarism, daily physically limitations, and poor quality of sleep. However, subgroup analysis revealed that these findings were primarily associated with MCS with comorbid FSS.

**Conclusions**

MCS was associated with lower socioeconomic status, physically inactivity and poor quality of sleep. Subgroup analysis revealed that several associations was explained by FSS comorbidity, i.e. MCS cases with no comorbid FSS showed normal rate of cohabitation and did not report physical limitations or difficulties sleeping. Overall, our findings emphasise the importance of screening MCS cases for FSS comorbidity both in epidemiological and clinical settings.

**Introduction**

Most people are on a regular basis exposed to a range of airborne chemicals that they may notice, but do not pay much attention to. Such exposures can be perfumed products, car exhaust, organic solvents and cooking fumes as some common examples [1,2]. It is also common to have experienced being bothered by such exposures to a degree that may be regarded as unpleasant or even be the cause of transient somatic discomfort [2,3]. However, for some individuals, these common airborne chemical exposures that most people consider to be benign, are associated with recurrent disabling physical reactions [4–6]. This condition, by the patients attributed to an acquired increase in sensitivity to airborne chemical, is often referred to as multiple chemical sensitivity (MCS). MCS patients constitute a highly heterogeneous group in term of symptom pattern and severity, level of sensitivity and the nature of exposures associated with symptom elicitation. Exposure agents associated with MCS symptoms are numerous and chemically diverse, and individuals afflicted with MCS often describe that symptoms appear when exposed to substances that carry an odour [5]. A traditional toxicological dose-response relationship between exposure levels and elicitation of symptoms or symptom severity does not exist for MCS [7,8], and some cases even report symptom elicitation upon an exposure that is below their sensory detection threshold [9]. The type and number of symptoms experienced by persons with MCS are likewise diverse, with common symptoms being severe headache/migraine and dizziness, respiratory symptoms, muscle and joint and pain [4,10–12].

Numerous and very diverse modes of action have been suggested to explain the MCS phenotype, with some of the more commonly proposed causal mechanisms being central pain sensitization, neurogenic inflammation, altered metabolic capacity, behavioural conditioning, and expectancy-induced nocebo effect [5,9,13–15]. However, scientific evidence supporting the suggested mode of action is still insufficient to reach consensus, and the underlying mechanisms leading to symptom elicitation in MCS remains an enigma. It is therefore a challenge how best to delimit MCS, and in the literature MCS case status is either determined based on self-reports (i.e. self-reported clinician diagnosed MCS [9]), self-assessment using validated questionnaire instruments [3,5,16,17]) or diagnoses by an experienced physician [18]. Consequently, reported prevalence rates of MCS vary considerable in the literature, with most estimates ranging from 0.5%-6.5% [2,12,19–21]. Likewise, a number of alternative labels...
are used in the literature to describe the same phenotype with chemical intolerance, environmental hypersensitivity, toxicant induced loss of tolerance and idiopathic environmental intolerances being some of the most commonly applied labels [7,22–25]. Presently, we use MCS without reference to any assumptions about the underlying etiology or causation.

MCS is currently categorized as a functional somatic syndrome (FSS), and MCS cases often meet the criteria for FSS subtypes such as fibromyalgia (FM), chronic fatigue syndrome (CFS) and irritable bowel syndrome (IBS) [5,26,27]. This symptomatic overlap between MCS and other types of FSSs represents a challenge when studying the epidemiology of MCS, and no consensus exists on how best to handle this potential influence of comorbid FSS. In some studies of MCS, cases fulfilling criteria for other types of FSSs are not identified, thereby ignoring the issue of comorbid FSS, whereas in others studies, cases with comorbid FSS are identified and excluded from the population in order to study a more “pure” form of MCS [17]. The later procedure was even recommended by Lacour and colleagues, but only for cases in which comorbid FSS had emerged before the development of MCS [22]. However, whether a strategy of excluding MCS cases with FSS comorbidity is scientifically sensible or whether it in fact contributes to a more selected and less representative study population is a matter of discussion.

So far, the epidemiology of MCS has predominantly been studied in clinical and occupational settings, and less in randomly selected general population-based samples [28]. General population-based cohort studies have played a significant role in unravelling the epidemiology of many chronic diseases [29,30], and has the advantages of being less prone to selection bias, provide reliable prevalence estimates, and can describe the natural history of a disease [31,32]. These methodological advantages advocate for a prioritization of more general population-based research when studying a disease such as MCS, for which both prevalence and aetiology remains poorly described [5,28,33,34]. The Danish Study of Functional Disorders (DanFunD) was initiated in 2011 to outline the epidemiology of FSSs and represents a general population-based longitudinal cohort study of nearly 10,000 adult Danes. In the DanFunD study, participants fulfilling criteria for MCS, FM, IBS, CFS and whiplash-associated disorders (WAD) were identified using standardized validated questionnaire-based delimitations [35]. These five types of FSS were chosen to represent the field of FSS, but other types of FSS could have been included instead, such as temporomandibular disorder, tension-type headache or pelvic pain syndromes. The results from the DanFunD study have shown that FSSs are prevalent in the general population and that a high level of mutual overlap between the five FSSs examined exist [26,36].

Using an epidemiological approach and data from the DanFunD study, the primary aim of this study was to characterize MCS phenotype regarding symptom triggers, symptom experienced and adjustment in lifestyle as well as describe the demographics, socioeconomic status and selected lifestyle factors associated with MCS. A secondary aim was to investigate whether MCS cases without comorbid FSS differs from MCS cases with comorbid FSS in the examined parameters.

Methods

Study population

The study population comprised a random sample of 29,088 persons drawn from the Danish Civil Registration System. A total of 9,656 (33.7%) accepted the invitation and participated in the DanFunD baseline examination conducted between 2011 and 2015 [35]. All participants were Danish citizens born in Denmark aged 18–76 years and living in one of 10 selected municipalities covering the western suburbs of the greater Copenhagen area, Denmark.
Case definition

Questionnaire data from DanFunD comprises information used to delimit five different FSSs in the cohort, i.e. MCS [22,37], FM [38], CFS [39,40], IBS [41] and WAD [42] as described in more detail by Petersen and colleagues [26]. Case criteria for MCS were constructed as an abridged adaptation of the 1999 US Consensus Criteria for MCS and the revisions suggested by Lacour and colleagues [22,37]. Hence, MCS case status was assigned to participants reporting widespread impairing symptoms and lifestyle adjustments as a result of their reactions to common airborne exposures (S1–S3 Tables), operationalized as follows

1. Have experienced symptoms upon being exposed to at least two of 11 common odours and airborne chemicals, and
2. have experienced at least one symptom from the central nervous system and at least one symptom from another organ system in response to inhalation of airborne odours or chemicals, and
3. Report significant lifestyle or functional impairment due to symptoms related to inhalation of airborne chemicals and odour, defined as; responding affirmably to: A) symptoms have influenced my choice of products used for personal hygiene, products used for cleaning at home, and/or choice of places where I do my daily shopping, and either B) symptoms have negatively influenced my social lifestyle (i.e. limited my possibility to use of public transport, dine at restaurants, go to the cinema/theatre, participate in meetings/social events) or C) symptoms have negatively influenced my occupational conditions (i.e. have had to go on temporary sick leave, discontinued education/employment, been unable to hold a job position or unable to complete an education).

All participants fulfilling criteria for MCS were subsequently divided into two subgroups, i.e. one subgroup with MCS cases with no comorbid FSS, and one subgroup with MCS cases fulfilling the criteria for at least one of the additional four FSS screened for in the DanFunD study.

Demographics and socioeconomic status. For descriptive analysis, participants were stratified into five age bands of 10 years (except for the most senior group covering 60–76 years of age). Cohabitation was divided into three categories married/cohabiting, formerly married/cohabited and never married/cohabited. Educational level was stratified into four categories beyond elementary school, i.e. skilled worker or <1 year of higher education, short vocational training/<3 years, medium length vocational training/3-4 years, and long vocational training/> 4 years. Occupational status comprised the three categories currently in occupation, formerly in occupation, and never having been in occupation. Participants were also asked to rate their subjective social status on a visual analogue scale ranging from one (lowest social status) to ten (highest social status). For analysis, the ratings were divided into three categories, i.e. those with low (1–4), middle (5–7) or high (8–10) subjective social status [43].

Lifestyle factors. Smoking was stratified into four categories (smoking daily, smoking occasionally, ex-smoker, never smoked regularly), dietary intake was estimated using a self-administered 26-item food frequency questionnaire, and stratified into three levels of diet (healthy, average, unhealthy) [44], weekly alcohol consumption was stratified into four categories (zero, 1–21 (men)/1-14 (women), 21–35 (men)/14-35 (women), ≥36 units/week), physical activity during leisure time was stratified into three categories (sedentary, low activity and medium/high activity) [45], being limited in daily activities was stratified into three categories (all the time/frequently, sometimes and almost never/never), problems falling asleep at night...
was stratified into three frequencies of difficulties falling asleep (2–4 times a month or less, 1–6 times a week, every night), and waking up earlier in the morning than anticipated was stratified into three frequencies of difficulties falling asleep (2–4 times a month or less, 1 or more times a week, every morning).

**Statistical analyses**

After completion of the data collection for the DanFunD study, a thorough inspection of all collected data was conducted by experienced statisticians. All measures were checked using standardised templates for handling of missing data and error values. In general, rates of missing data in the DanFunD study are low, and in this specific study the rate is below 5%, and for FSS below 3%.

Statistical analyses were performed using SPSS for Windows (version 22; IBM Corp, Armonk, NY). All p-values were two-sided, and p-values <0.05 were considered statistically significant. Participants were divided into four groups: 1) MCS all = all cases fulfilling criteria for MCS; 2) MCS ÷ FSS = cases fulfilling criteria for MCS, but not for any of the four additional FSS in the DanFunD study; 3) MCS + FSS = Cases fulfilling criteria for MCS and at least one other FSS; and 4) Controls = not fulling criteria for any of the five FSS examined. Descriptive statistics for the four groups are presented as % (n) or mean (standard deviation, SD). Each of the three MCS groups were compared to the control group, and the MCS ÷ FSS subgroup was compared with the MCS + FSS subgroup. For all group comparisons, Pearson Chi-squared tests were used for all categorical variables, i.e. data used to delimit MCS (Fig 1/S1 Table; Fig 2/S2 Table; Fig 3/S3 Table), and demographic, socioeconomic and lifestyle data. Independent sample t-test was used for numerical variables (age as a continues variable). By means of logistic regression analysis, sex as a five class categorial variable was adjusted for age, whereas data on chemical hypersensitivity, socioeconomics and lifestyle parameters were adjusted for age and sex. Sex as a continuous variable was adjusted for age by means of simple linear regression analysis [26,46].

**Ethical approval.** All research reported here was conducted in accordance with the Helsinki Declaration. All participants gave written informed consent before participating, and the study was approved by the Ethical Committee of Copenhagen County (Ethics Committee: KA-2006-0011; H-3-2011-081; H-3-2012-0015) and the Danish Data Protection Agency.

![Fig 1. Prevalence of participants that have experienced unpleasant reactions when exposed to any of these 11 types of common odours or airborne chemicals. Abbreviations: MCS = Multiple chemical sensitivity; FSS = functional somatic syndrome; MCS all = all participants meeting criteria for multiple chemical sensitivity; MCS + FSS; participants meeting criteria for multiple chemical sensitivity and one or more comorbid FSS. MCS ÷ FSS = participants meeting criteria for multiple chemical sensitivity but not comorbid FSS.](https://doi.org/10.1371/journal.pone.0246461.g001)
Results

Functional somatic syndromes

A total of 188 (1.95%) persons in the DanFunD cohort fulfilled the criteria for MCS, whereas 7,971 (82.5%) did not fulfil criteria for any of the five FSSs in question (Table 1). Of the 188 identified MCS cases, 109 (1.1% of the cohort/61.2% of all MCS cases) only fulfilled criteria for MCS, and were assigned to the MCS with no comorbid FSS subgroup, and 73 cases (0.8% of cohort/38.8% of all MCS cases) fulfilled the criteria for one or several of the additional four FSSs, and were assigned to the MCS with comorbid FSS subgroup. Most common FSS comorbidity among the MCS cases were CFS (51 cases) followed by FM (30 cases), IBS (19 cases) and WAD (9 cases). Six MCS cases could not be assigned to either of the two MCS subgroups due to missing questionnaire data on comorbid FSS status. Hence, those cases were not included in the comparison of MCS cases with and without comorbid FSS. Cases with MCS were more often females, independently of FSS comorbidity, whereas age did not
differ between MCS cases and controls or between the MCS cases with or without comorbid

FSS (Table 1).

Airborne chemical exposure related to unpleasant reactions

All questions used to delimit MCS (S1–S3 Tables) were also found to be positively associated with MCS case status (except for the MCS + FSS group not being associated with urinary tract symptoms). Of the 11 types of chemical exposure included in the questionnaire (Fig 1, S1 Table), other persons use of perfumed products, motor vehicle exhaust and cleaning agents were the exposure types most frequently reported to be the cause of unpleasant reactions upon inhalation, both among controls and MCS cases (Fig 1; S1 Table). Reports of unpleasant reactions caused by inhalation of motor vehicle exhaust were more common among MCS cases with comorbid FSS than MCS cases with no co-morbid FSS (Fig 1; S1 Table).

Symptoms related to inhalation of airborne chemicals

The most common symptoms reported by the MCS cases and controls upon inhalation of airborne chemicals and odours (Fig 2; S2 Table) were symptoms from the ocular and respiratory system and headaches from the central nervous system (Fig 2; S2 Table). Symptoms from the nose, eyes, lungs, exhaustion/fatigue, giddiness and heart/chest were more frequently reported by MCS cases with comorbid FSS compared to MCS cases with no co-morbid FSS (Fig 2; S2 Table).

Consequences in daily life related to inhalation of airborne chemicals

Nearly 90% of the MCS cases and 39% of the controls reported that symptoms related to inhalation of odours and airborne chemicals have influenced their choice of products used for personal hygiene, and 80% of the MCS cases and 25% of the controls had made changes related to the choice of cleaning products used domestically (Fig 3, S3 Table). Furthermore, 53% of the MCS cases and 10% of the controls reported that symptoms associated with odours and

Table 1. Demographic characteristics of participants in the DanFunD study fulfilling criteria for multiple chemical sensitivity (MCS) and of controls not fulfilling the criteria for any of five functional somatic syndromes (FSSs).

|                          | MCS all (n = 188) | MCS + FSS comorbidity (n = 73) | MCS − FSS comorbidity (n = 109) | Controls − FSS (n = 7791) |
|-------------------------|------------------|---------------------------------|---------------------------------|---------------------------|
| **Sex % (n)**           |                  |                                 |                                 |                           |
| Men                     | 33.0 (62)*       | 27.4 (20)*                      | 38.5 (42)*                      | 48.9 (3812)               |
| Women                   | 67.0 (126)*      | 72.6 (53)*                      | 61.5 (37)*                      | 51.1 (3979)               |
| **Age, mean (SD)**      |                  |                                 |                                 |                           |
| 18–29                   | 53.6 (13.5)      | 51.3 (13.4)                     | 54.8 (13.8)                     | 52.7 (13.1)               |
| 30–39                   | 8.5 (16)         | 9.6 (7)                         | 8.3 (9)                         | 7.3 (572)                 |
| 40–49                   | 9.6 (18)         | 13.7 (10)                       | 7.3 (8)                         | 9.1 (706)                 |
| 50–59                   | 14.9 (28)        | 16.4 (12)                       | 12.8 (14)                       | 21.2 (1650)               |
| 60–76                   | 26.1 (49)        | 27.4 (20)                       | 25.7 (28)                       | 25.1 (2018)               |
|                          | 41.0 (77)        | 32.9 (24)                       | 45.8 (50)                       | 36.5 (2845)               |

Standard deviation (SD).

MCS all: All participants meeting criteria for MCS. MCS + FSS: Participants meeting criteria for MCS and one or more comorbid FSS. MCS − FSS: Participants meeting criteria for MCS but not comorbid FSS.

*Pearson Chi-square test comparing MCS groups with controls and MCS subgroups with each other (p<0.05), adjusted for age.

** Pearson Chi-square test comparing MCS groups with controls and MCS subgroups with each other (p<0.05), no significant differences.

†Independent samples t-test comparing MCS groups with controls (p<0.05), no significant differences.

https://doi.org/10.1371/journal.pone.0246461.t001
airborne chemicals had affected their shopping habits. However, only MCS cases reported that symptoms related to inhalation of airborne chemicals had affected their social life or occupational conditions (Fig 3, S3 Table).

Demographics and socioeconomics

A larger percentage of the MCS cases with comorbid FSS were living alone compared to both the MCS cases without comorbid FSS and the controls, whereas educational level for all MCS cases were comparable to controls (Table 2). Fewer MCS cases were in current occupation compared to the controls, and the MCS cases considered their own position in society to be lower than reported by controls, independently of FSS comorbidity (Table 2). Regarding subjective social status, no group differences was observed for the middle group to which most cohort participants belonged too, whereas the MCS cases were more likely to consider themselves as having low socioeconomic position and less likely to view it to be high compared to controls.

Lifestyle

Regarding lifestyle measures (Table 3), the MCS cases reported dietary and smoking habits that were comparable to those of the controls, as well as comparable level of alcohol consumption. These findings were independent of comorbid FSS status, except for the MCS cases with no comorbid FSS being more likely to consume more alcohol than recommend (21–35 (men)/
Table 3. Selected lifestyle factors of participants meeting criteria for multiple chemical sensitivity (MCS) and of controls not meeting the criteria for any of five functional somatic syndromes (FSS).

|                          | MCS all (n = 188) | MCS + FSS comorbidity (n = 73) | MCS \(\div\) FSS comorbidity (n = 109) | Controls \(\div\) FSS (n = 7791) |
|--------------------------|-------------------|-------------------------------|----------------------------------------|-------------------------------|
| **Diet % (n)**           |                   |                               |                                        |                               |
| Healthy                  | 24.2 (45)         | 22.5 (16)                     | 24.8 (27)                              | 23.0 (1776)                  |
| Average                  | 65.6 (122)        | 64.8 (46)                     | 66.1 (72)                              | 66.4 (5131)                  |
| Unhealthy                | 10.2 (19)         | 12.7 (9)                      | 9.2 (10)                               | 10.6 (822)                   |
| **Smoking % (n)**        |                   |                               |                                        |                               |
| Daily                    | 13.9 (26)         | 15.1 (11)                     | 13.8 (15)                              | 12.1 (943)                   |
| Occasionally             | 2.7 (5)           | 1.4 (1)                       | 3.7 (4)                                | 3.0 (250)                    |
| Ex-smokers               | 44.9 (84)         | 44.4 (32)                     | 46.8 (51)                              | 37.5 (2908)                  |
| Never been a daily smoker | 38.5 (72)       | 38.9 (28)                     | 35.8 (39)                              | 47.0 (3660)                  |
| **Alcohol % (n)**        |                   |                               |                                        |                               |
| Zero                     | 17.4 (29)*        | 17.7 (11)*                    | 18.0 (18)*                             | 9.5 (707)                    |
| 1–21 (men)/1–14 (women)  | 70.1 (117)        | 77.4 (48)                     | 65.0 (65)                              | 80.2 (5970)                  |
| 21–35 (men)/14–35 (women)| 9.0 (15)          | 1.6 (1)                       | 13.0 (13)†                             | 8.5 (633)                    |
| ≥36 units/week           | 3.6 (6)           | 3.2 (2)                       | 4.0 (4)†                               | 1.8 (137)                    |
| **Physical activity, leisure time % (n)** |                   |                               |                                        |                               |
| Sedentary                | 17.3 (32)         | 26.8 (19)                     | 11.1 (12)                              | 11.5 (886)                   |
| Low activity             | 56.8 (105)        | 54.9 (39)                     | 57.4 (62)                              | 55.1 (4260)                  |
| Medium/high activity      | 25.9 (48)         | 18.3 (13)                     | 31.5 (34)                              | 33.5 (2588)                  |
| **Limited in daily activities (such as using a bike cycle, domestic housework, moving a table) % (n)** |                   |                               |                                        |                               |
| All the time/frequently  | 12.9 (24)         | 20.0 (27.8)                   | 2.8 (3)                                | 1.6 (127)                    |
| Sometimes                | 22.0 (41)         | 33.3 (24)                     | 15.7 (17)                              | 5.8 (448)                    |
| Almost never/never        | 65.1 (121)        | 38.9 (38.9)                   | 81.5 (88)                              | 92.6 (7177)                  |
| **Problems falling asleep % (n)** |                   |                               |                                        |                               |
| 2–4 times a month or less| 63.1 (118)        | 55.6 (40)                     | 67.0 (73)                              | 75.8 (5876)                  |
| 1 or more times a week    | 33.7 (63)         | 38.9 (28)                     | 31.2 (34)                              | 22.9 (1774)                  |
| Every day                | 6.0 (3.2)         | 5.6 (4)                       | 1.8 (2)†                               | 1.3 (103)                    |
| **Waking up earlier in the morning than anticipated % (n)** |                   |                               |                                        |                               |
| 2–4 times a month or less| 46.2 (86)         | 30.6 (22)                     | 56.5 (61)                              | 67.1 (5205)                  |
| 1 or more times a week    | 34.4 (64)         | 37.5 (27)                     | 33.3 (36)                              | 25.1 (1948)                  |
| Every day                | 19.4 (36)         | 31.9 (23)                     | 10.2 (11)                              | 7.7 (600)                    |

MCS all: All participants meeting criteria for MCS. MCS + FSS; participants meeting criteria for MCS and one or more comorbid FSS. MCS \(\div\) FSS; participants meeting criteria for MCS but not comorbid FSS.

* Pearson Chi-square test comparing MCS groups with controls (p < 0.05), adjusted for sex and age.
† Pearson Chi-square test comparing MCS \(\div\) FSS comorbidity with MCS + FSS comorbidity, adjusted for sex and age.

14-35 (women) units per week) compared to the MCS cases with FSS comorbidity. MCS was associated with a more sedentary lifestyle during leisure time, but only in the MCS all group and the MCS group with comorbid FSS; not in the MCS subgroup with no FSS comorbidity. The MCS cases also considered themselves to be more limited in daily activities than the controls, and this limitation in physical capacity in daily life was more pronounced among the MCS cases with comorbid FSS. Frequent problems falling asleep at night and problems waking up earlier than anticipated in the morning was also associated with MCS all and MCS with comorbid FSS, but not with MCS cases with no comorbid FSS.
Discussion

In this study we utilized data from the DanFunD study to describe socioeconomic status and lifestyle characteristics associated with MCS and explored the consequences of having MCS with FSS comorbidity. Epidemiological studies examining lifestyle characteristics of persons with MCS are few, and to our knowledge, no other population-based study has in parallel examined the impact of MCS and FSS comorbidity. We also examined the level of chemical sensitivity in the general population, and in line with earlier findings our results emphasize that being bothered and experiencing symptoms when exposed to common odours and airborne chemicals is a normal phenomenon in the general population [2,4,5,47–52]. However, the consequences associated with such exposures in terms of number of symptoms experienced and enforced lifestyle adjustments were significantly fewer in the control group, with the majority not being bothered at all. These results are in accordance with results from other general population-based studies from Denmark, Sweden, USA and Germany [2–4,12,51]. Among MCS cases, only few differences were identified between those with and those without comorbid FSS based on questions used to delimitate MCS (Figs 1–3, S1–S3 Tables). This suggests that the level of sensitivity towards everyday exposures is similar between these MCS subgroups. The only differences observed were that MCS cases with comorbid FSS reported a higher overall symptom burden and were more likely to have experienced unpleasant reactions caused by inhalation of motor vehicle exhaust.

Demographic and socioeconomic characterisation

In line with existing literature, we found an association between MCS and female sex [5,19,53,54]. As for age, we found no differences between MCS cases and controls. This is comparable to the findings from two recent studies of a Finnish population-based cohort [53] and a Canadian clinical cohort [54], but differs from that found in recent Swedish and Finnish population-based cohorts, in which chemical intolerance was found to be associated with high age [53]. Regarding socioeconomic status, we found that education was not associated with MCS, and that only MCS cases with comorbid FSS were more likely to be living alone. Furthermore, we found that MCS cases were less likely to be in current occupation, and that they reported lower subjective social status than controls. These educational and occupational characteristics are similar to previous studies of both MCS [2,55–57] and other types of FSS [58,59], and it has been suggested that the typical MCS patient is a middle-aged well-educated female [56,60,61]. However, the socioeconomic characteristics presented in the literature is not consistent. For example, Kreutzer and colleagues (1999) found that neither marital status, employment nor education were predictive of MCS in a telephone administrated survey of about 4,000 subjects, representing the general population. They proposed that the inconsistencies observed concerning socioeconomic status throughout the literature are likely a consequence of the various delimitations of MCS/chemical intolerance applied [19]. Based on the cross-sectional data presented in this manuscript, it is not possible to conclude whether lower socioeconomic position and reduced labour marked attachment preceded the progression of MCS or whether it is merely a consequence of the various limitations found to be associated with MCS. However, since educational level of the MCS cases in DanFunD were found to be comparable to that of controls, and that decreased levels of cohabitation was only associated with MCS with comorbid FSS, our data may support the latter.

Lifestyle characteristics

Regarding lifestyle factors, we found no difference between participants with MCS and the controls in regard to daily dietary intake, smoking habits or alcohol consumption, except for a
higher percentage of MCS cases not consuming any alcohol (Table 3). How these findings coincide with the literature is uncertain, as studies examining daily dietary habits and nutrient intakes among persons with MCS are surprisingly rare. Instead, more studies of MCS have investigated the potential positive effect of implementing various forms of specialized nutritional/dietary intervention programs, such as diverse intake of nutritional supplement and exclusion or rotation diet, primarily in smaller case-control setting [9,34,62,63]. However, our findings are in line with that reported from studies of associated diseases, in which daily intake of calories or overall dietary habits have been comparable between FSS cases and healthy controls [64,65]. Several previous studies of MCS have also found lower rate of daily smokers among MCS subjects, and it has been suggested that persons with MCS often avoid being exposed to exogenous chemicals, such as motor vehicle exhaust and tobacco smoke [54,57,66,67]. However, findings on alcohol consumption or smoking frequency in MCS subjects are not consistent, and studies based on data from the Finnish Twin-cohort found that individuals reporting symptom elicitation in response to common airborne chemical exposures were more likely to be current smokers and have higher alcohol consumption than controls [68,69].

Regarding physical capacity and sleep, we found that MCS is associated with a more sedentary lifestyle, with more physical limitations in daily life and more disturbed sleep. Though, these associations were more pronounced in the subgroup of MCS cases with FSS comorbidity. Similar associations between MCS and poor quality of sleep and low physical capacity has also been reported in both clinical and population-based studies of MCS. In a recent clinical study from Spain, 27% of MCS patients reported a sedentary lifestyle and 60% rated themselves to be barely active. Furthermore, half of the patients reported their average quality of sleep as “poor or insufficient” and 38% as being of “moderate” quality [63]. Moreover, sleep disturbance has also been found to be associated with MCS in a Swedish population-based cohort [70] and in other types of FSS [71–73]. Common symptoms associated with MCS and FSS in general, such as myalgia, tenderness and fatigue, can also be caused or exacerbated by prolonged periods of nonrestorative sleep [73], why prolonged periods with poor quality of sleep may contribute to aggravation of symptom level in MCS.

Summary and implications

In summary, we found MCS to be associated with low socioeconomic status, low physical capacity in daily life and poor quality of sleep. Moreover, our results emphasize the importance of taking comorbid FSS into account when studying MCS, as the total disease burden seems to be noticeably lower for MCS cases with no comorbid FSS. How best to handle this issue of FSS comorbidity when studying MCS is, however, open for discussion. Some studies of MCS exclude participants with comorbid FSS as an attempt to eliminate the interferences of FSS comorbidity [17,22,74]. However, this approach will undoubtedly lead to a more selective and thus less representative study population and introduce considerable risk of selection bias. On the other hand, it is important to address how FSS comorbidity may influence study findings, and if the number of cases allows for it, subgroup analysis as conducted in this study can provide a more comprehensive insight into the MCS phenotype. With smaller study samples, this strategy may not be applicable, and hence a more pragmatic approach must be applied. Consequently, whether to exclude MCS cases with comorbid FSS or not will depend on the research question and the size of the study population.

In addition to the epidemiological description of MCS, our analyses reveal that adverse reactions to everyday chemical exposure is also prevalent among controls. Almost 40% of controls reported unpleasant reactions and making adjustments in everyday life because of,
seemingly, safe chemical exposures. Similar results have been published before [2,4,5,49–51,53], and consequently, we suggest two implications of this pattern: First, adverse reactions to chemicals is arguably the distinguishing criterion for defining MCS. However, reactions to scented products are so common in the general population that the line between cases and controls runs the risk of becoming blurred. It may at least partly explain the vague, heterogeneous nature of MCS, and calls for future discussions on how MCS should be defined. Second, the reactions to everyday chemicals and odours, and the related lifestyle adjustments suggest that such exposures are of concern in hypersensitive individuals in general. It may be necessary in the future to discuss these exposures in the way that is currently done for e.g. noise [75,76].

Strengths and limitations

An important strength of this study is the large random sample of the general adult population enrolled in the DanFunD study, comprising both sexes over an age span of 50 years, and the vast amount of data collected for the study [35]. These data offer a unique opportunity within MCS research to study the epidemiology of MCS in a large and well characterized cohort, and to investigate the role of comorbid FSS. Regarding the limitations, a concern is the relatively low participation rate of the DanFunD study at 33.7%, and whether the cohort is representative of the general adult population.

A comparison between respondents and non-respondents enrolled in a comparable cohort, the Health2006 study covering the same geographical area as DanFunD, did show some differences with respect to sociodemographic characteristics, education and use of health services [77]. For example, respondents were older and better educated, and had a higher personal income than non-respondents. Other differences included larger proportion of men and more individuals living alone as well as more events of hospitalization and more days of hospitalization among the non-respondents. We expect similar differences between responders and non-responders in the DanFunD cohort, but how these differences may influence the study findings is difficult to assess. It is obviously important to take these differences into consideration when results from the DanFunD study are used to generalize on a population level. Nevertheless, we expect the selection bias to have influenced the recruitment of participants with an FSS in a similar manner, resulting in a fair representation of the general population. Hence, we believe that our results are generalizable.

The questionnaire used to delimit MCS in DanFunD was first used in the Health2006 study [77], where it was tested for linguistic comprehension, reproducibility, relevance and reliability in a pilot group setting, consisting of individuals with self-reported chemical sensitivity [2]. It was concluded that the questions have good reproducibility, and a fair concordance for both positive and negative answers [2], supporting the applicability of the questionnaire as a tool to study MCS in the general population. To identify MCS cases in the cohort, we used a delimitation inspired by, but not identical to, the criteria suggested by the 1999 US Consensus Criteria for MCS and the revision suggested by Lacour and colleagues [22,37]. Three criteria have not been included in our delimitation, i.e. “Are the condition chronic (symptoms been present for at least six months)?”, “Do symptoms appear upon being exposed to chemicals in low levels (lower than previously or commonly tolerated)” and “Do symptom improve or resolve when the incitants are removed?” [22,37]. These characteristics of MCS are highly relevant in assessments of MCS patients in clinical settings but were found to be less applicable when screening a large general population-based cohort for participants with an MCS-like phenotype. Nevertheless, it is a possible limitation to the study that results were based on self-reported symptoms and self-reported lifestyle impairments in questionnaires. Although standard epidemiological FSS delimitations were applied, FSS case status was not verified clinically by an experienced
physician. This increases the risk of some FSS cases being false positive and findings from this study may not be reproducible in clinical samples of MCS.

Conclusions and perspectives

In this study we present in detail the questionnaire tool and algorithm used to delimitate MCS in the DanFund study, as well as selected characteristics of cases with MCS identified in the cohort. We also examined the importance of FSS comorbidity on disease severity. In conclusion, the results suggest that MCS is associated with female sex and low occupational status, low subjective social status, low physical capacity in daily life and poor quality of sleep. MCS cases did not differ from controls with regards to age, education, dietary habits, smoking or weekly alcohol consumption. Moreover, subgroup analyses suggest that the associations between MCS and sedentary lifestyle, physical limitations in daily activities, and poor quality of sleep can almost completely be explained by the presence of FSS comorbidity. Subgroup analyses also revealed that MCS cases with comorbid FSS are more likely to be living alone than both MCS cases with no comorbid FSS and controls. Our finding emphasises the importance of screening MCS cases for FSS comorbidity in future studies of MCS and in clinical assessment of MCS patients.

Supporting information

S1 Table. Prevalence of participants who have experienced unpleasant reactions when exposed to the 11 types of common odours or airborne chemicals.
(DOCX)

S2 Table. Prevalence of symptoms reported to be associated with inhalation of airborne chemicals.
(DOCX)

S3 Table. Prevalence of participants who reported adjustment of behaviour due to symptoms related to inhalation of airborne chemicals.
(DOCX)

Acknowledgments

The authors will like to thank the participants in the DanFunD cohort and the staff behind the cohort at the Center for Clinical Research and Prevention, Bispebjerg & Frederiksberg Hospital, Capital Region of Denmark for their great work in collecting and assuring data of high quality. The authors would also like to thank the Danish Study of Functional Disorders (DanFunD). The DanFunD scientific management group consists of professor, DMSci Torben Jørgensen (principal investigator); professor, DMSci Per Fink; senior consultant, Ph.D. Lene Falgaard Eplov; M.Sc., Ph.D. professor Susanne Brix Pedersen; MD, Ph.D. Michael Benros; M. Sc., Professor, MD PhD Allan Linneberg and DanFunD scientific officer MSc, Ph.D. Thomas M Dantoft.

Author Contributions

Conceptualization: Thomas Meinertz Dantoft, Steven Nordin, Linus Andersson, Marie Weinreich Petersen, Sine Skovbjerg, Torben Jørgensen.

Data curation: Thomas Meinertz Dantoft, Sine Skovbjerg, Torben Jørgensen.
Formal analysis: Thomas Meinertz Dantoft, Marie Weinreich Petersen, Sine Skovbjerg, Torben Jørgensen.

Investigation: Thomas Meinertz Dantoft, Marie Weinreich Petersen, Sine Skovbjerg, Torben Jørgensen.

Methodology: Thomas Meinertz Dantoft, Steven Nordin, Linus Andersson, Marie Weinreich Petersen, Sine Skovbjerg, Torben Jørgensen.

Project administration: Thomas Meinertz Dantoft.

Supervision: Steven Nordin, Torben Jørgensen.

Validation: Thomas Meinertz Dantoft, Marie Weinreich Petersen, Torben Jørgensen.

Writing – original draft: Thomas Meinertz Dantoft.

Writing – review & editing: Thomas Meinertz Dantoft, Steven Nordin, Linus Andersson, Marie Weinreich Petersen, Sine Skovbjerg, Torben Jørgensen.

References

1. Miller CS, Prihoda TJ. The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications. Toxicol Ind Health. 1999; 15(3–4):370–85. https://doi.org/10.1177/074823379901500311 PMID: 10416289

2. Berg ND, Linneberg A, Dirksen A, Elberling J. Prevalence of self-reported symptoms and consequences related to inhalation of airborne chemicals in a Danish general population. Int Arch Occup Environ Health. 2008; 81(7):881–7. https://doi.org/10.1007/s00420-007-0282-0 PMID: 18058120.

3. Berg ND, Linneberg A, Dirksen A, Elberling J. Phenotypes of individuals affected by airborne chemicals in the general population Int Arch Occup Environ Health. 2009; 82(4):509–17. https://doi.org/10.1007/s00420-008-0352-y PMID: 18751996

4. Hausteiner C, Bornschein S, Hansen J, Zilker T, Forstl H. Self-reported chemical sensitivity in Germany: a population-based survey. Int J Hyg Environ Health. 2005; 208(4):271–8. https://doi.org/10.1016/j.ijheh.2005.03.006 PMID: 16078641

5. Dantoft TM, Andersson L, Nordin S, Skovbjerg S. Chemical intolerance. Curr Rheumatol Rev. 2015; 11(2):167–84. Epub 2015/06/20. https://doi.org/10.2174/157339711102150702111101 PMID: 26088215.

6. Steinemann A. National Prevalence and Effects of Multiple Chemical Sensitivities. J Occup Environ Med. 2018; 60(3):e152–e6. Epub 2018/01/13. https://doi.org/10.1097/JOM.0000000000001272 PMID: 29329146.

7. Miller CS. The compelling anomaly of chemical intolerance. Ann N Y Acad Sci. 2001; 933:1–23.1–23. https://doi.org/10.1111/j.1749-6632.2001.tb05810.x PMID: 12000012

8. Cohn JR. Multiple chemical sensitivity or multi-organ dysesthesia. J Allergy Clin Immunol. 1994; 93(6):953–4. Epub 1994/06/01. https://doi.org/10.1016/0091-6749(94)70041-9 PMID: 8006316.

9. NICNAS, OCSEH. Multiple Chemical Sensitivity: Identifying Key Research Needs; National Industrial Chemicals Notification and Assessment Scheme, Australia; Office of Chemical Safety and Environmental Health, Australia. 2010. Report No.: 1.

10. Lessof M. Report of Multiple Chemical Sensitivities (MCS) Workshop, Berlin, Germany, 21–23 February 1996. PICS/96.29 IPCS, Geneva, Switzerland. Hum Exp Toxicol. 1997; 16(4):233–4. https://doi.org/10.1177/096032719701600414 PMID: 9154450

11. Wolkoff P, Nielsen GD. Effects by inhalation of abundant fragrances in indoor air—An overview. Environ Int. 2017; 101:96–107. Epub 2017/01/28. https://doi.org/10.1016/j.envint.2017.01.013 PMID: 28126407.

12. Caress SM, Steinemann AC. A review of a two-phase population study of multiple chemical sensivities. Environ Health Perspect. 2003; 111(12):1490–7. Epub 2003/09/02. https://doi.org/10.1289/ehp.5940 PMID: 12948889.

13. Nordin S. Mechanisms underlying nontoxic indoor air health problems: A review. Int J Hyg Environ Health. 2020; 226:113489. Epub 2020/03/13. https://doi.org/10.1016/j.ijhyg.2020.113489 PMID: 32163882

14. Van den Bergh O, Devriese S, Winters W, Vulemans H, Nemery B, Eelen P, et al. Acquiring symptoms in response to odors: a learning perspective on multiple chemical sensitivity. Ann N Y Acad Sci. 2001; 933:278–90. Epub 2002/05/10. https://doi.org/10.1111/j.1749-6632.2001.tb05831.x PMID: 12000028.
15. Van den Bergh O, Brown R, Petersen S, Witthöft M. Idiopathic Environmental Intolerance: A comprehensive model Clin Psychol Sci. 2017; 5(3):551–67. https://doi.org/10.1177/2167702617693327.

16. Nordin S, Millqvist E, Lowhagen O, Bende M. A short Chemical Sensitivity Scale for assessment of airway sensory hyperreactivity. Int Arch Occup Environ Health. 2004; 77(4):249–54. Epub 2004/03/17. https://doi.org/10.1007/s00420-004-0504-7 PMID: 15024570.

17. Rossi S, Pitidis A. Multiple Chemical Sensitivity: Review of the State in Epidemiology, Diagnosis, and Future Perspectives. J Occup Environ Med. 2018; 60(2):138–46. Epub 2017/11/08. https://doi.org/10.1097/JOM.0000000000001215 PMID: 29111991.

18. Berg ND, Rasmussen HB, Linneberg A, Brasch-Andersen C, Fenger M, Dirksen A, et al. Genetic susceptibility factors for multiple chemical sensitivity revisited. Int J Hyg Environ Health. 2010; 213(2):131–9. Epub 2010/02/27. https://doi.org/10.1016/j.ijheh.2010.02.001 PMID: 20185366.

19. Kreutzer R, Neutra RR, Lashuay N. Prevalence of people reporting sensitivities to chemicals in a population-based survey. Am J Epidemiol. 1999; 150(1):1–12. https://doi.org/10.1093/oxfordjournals.aje.a009908 PMID: 10400546.

20. Steinemann A. Prevalence and effects of multiple chemical sensitivities in Australia. Prev Med Rep. 2018; 10:191–4. Epub 2018/06/06. https://doi.org/10.1016/j.pmedr.2018.03.007 PMID: 29868366.

21. Park J, Gilmour H. Medically unexplained physical symptoms (MUPS) among adults in Canada: Comorbidity, health care use and employment. Health Rep. 2017; 28(3):3–8. Epub 2017/03/16. PMID: 28295128.

22. Lacour M, Zunder T, Schmidtko K, Vaith P, Scheidt C. Multiple chemical sensitivity syndrome (MCS)—suggestions for an extension of the U.S. MCS case definition. Int J Hyg Environ Health. 2005; 208(3):141–51. https://doi.org/10.1016/j.ijheh.2005.01.017 PMID: 15971853.

23. Graveling RA, Pilkington A, George JP, Butler MP, Tannahill SN. A review of multiple chemical sensitivity. Occup Environ Med. 1999; 56(2):73–85. https://doi.org/10.1136/oem.56.2.73 PMID: 10448311.

24. Park J, Knudson S. Medically unexplained physical symptoms. Health Rep. 2007; 18(1):43–7. PMID: 17441443.

25. Sears ME. The Medical Perspective on Environmental Sensitivities. 2007.

26. Petersen MW, Schroder A, Jorgensen T, Ombel E, Dantoft TM, Eliasen M, et al. Prevalence of functional somatic syndromes and bodily distress syndrome in the Danish population: the DanFunD study. Scand J Public Health. 2019; 1403494819868592. Epub 2019/09/15. https://doi.org/10.1177/1403494819868592 PMID: 31490218.

27. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet. 1999; 354(9182):936–9. https://doi.org/10.1016/S0140-6736(98)08320-2 PMID: 10489869.

28. Kreutzer R. MCS: the status of population-based research. Int J Hyg Environ Health. 2002; 205(5):411–4. Epub 2002/08/14. https://doi.org/10.1078/1438-4639-00167 PMID: 12173542.

29. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014; 383(9921):999–1008. https://doi.org/10.1016/S0140-6736(13)61752-3 PMID: 24084292.

30. Sorlie P, Wei GS. Population-based cohort studies: still relevant? J Am Coll Cardiol. 2011; 58(19):2010–3. Epub 2011/10/29. https://doi.org/10.1016/j.jacc.2011.08.020 PMID: 22032715.

31. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003; 20(1):54–60. Epub 2003/01/21. https://doi.org/10.1136/emj.20.1.54 PMID: 12533370.

32. Coggon DD, Rose GA, Barker DJP. Epidemiology for the uninitiated. 5th ed./Coggon D., Rose Geoffrey, Barker D.J.P. ed. London: BMJ; 2003.

33. Hu H, Baines C. Recent insights into 3 underrecognized conditions: Myalgic encephalomyelitis-chronic fatigue syndrome, fibromyalgia, and environmental sensitivities-multiple chemical sensitivity. Can Fam Physician. 2018; 64(6):413–5. Epub 2018/06/15. PMID: 29898928.

34. Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: review. Curr Opin Otolaryngol Head Neck Surg. 2007; 15(4):274–80. https://doi.org/10.1097/00006014-200706000-00005 PMID: 17629093.

35. Dantoft TM, Ebstrup JF, Linneberg A, Skovbjerg S, Madsen AL, Mehtsen J, et al. Cohort description: The Danish study of Functional Disorders. Clinical Epidemiology. 2017. Volume 9:127–39. https://doi.org/10.2147/CLEP.S129335 PMID: 28275316.

36. Petersen MW, Schroder A, Jorgensen T, Ombel E, Meinertz Dantoft T, Eliasen M, et al. Irritable bowel, chronic widespread pain, chronic fatigue and related syndromes are prevalent and highly overlapping in the general population: DanFunD. Sci Rep. 2020; 10(1):3273. Epub 2020/02/26. https://doi.org/10.1038/s41598-020-60318-6 PMID: 32094442.
37. Multiple chemical sensitivity: a 1999 consensus. Arch Environ Health. 1999; 54(3):147–9. https://doi.org/10.1080/0003989999062251 PMID: 10444033

38. White KP, Harth M, Speechley M, Ostbye T. Testing an instrument to screen for fibromyalgia syndrome in general population studies: the London Fibromyalgia Epidemiology Study Screening Questionnaire. J Rheumatol. 1999; 26(4):880–4. PMID: 10229410

39. Cella M, Chalder T. Measuring fatigue in clinical and community settings. J Psychosom Res. 2010; 69(1):17–22. https://doi.org/10.1016/j.jpsychores.2009.10.007 PMID: 20630259

40. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993; 37(2):147–53. https://doi.org/10.1016/0022-3999(93)90081-p PMID: 8463991

41. Kay L, Jorgensen T. Redefining abdominal syndromes. Results of a population-based study. Scand J Gastroenterol. 1996; 31(5):469–75. https://doi.org/10.3109/00365529609006767 PMID: 8734344.

42. Kasch H, Qerama E, Kongsted A, Bendix T, Jensen TS, Bach FW. Clinical assessment of prognostic factors for long-term pain and handicap after whiplash injury: a 1-year prospective study. Eur J Neurol. 2008; 15(11):1222–30. https://doi.org/10.1111/j.1468-1331.2008.02301.x PMID: 18003651

43. Singh-Manoux A, Adler NE, Marmot MG. Subjective social status: its determinants and its association with measures of ill-health in the Whitehall II study. Soc Sci Med. 2003; 56(6):1321–33. Epub 2003/02/26. https://doi.org/10.1016/s0277-9536(02)01131-4 PMID: 12600368.

44. Toft U, Kristoffersen LH, Lau C, Borch-Johnsen K, Jorgensen T. The Dietary Quality Score: validation and association with cardiovascular risk factors: the Inter99 study. Eur J Clin Nutr. 2007; 61(2):270–8. https://doi.org/10.1038/sj.ejcn.1602503 PMID: 16929244.

45. Saltin B, Grimby G. Physiological analysis of middle-aged and old former athletes. Comparison with still active athletes of the same ages. Circulation. 1968; 38(6):1104–15. Epub 1968/12/01. https://doi.org/10.1161/01.cir.38.6.1104 PMID: 5721960.

46. Palmquist E, Claesson AS, Neely G, Stenberg B, Nordin S. Overlap in prevalence between various types of environmental intolerance. Int J Hyg Environ Health. 2014; 217(4–5):427–34. Epub 2013/09/14. https://doi.org/10.1016/j.ijheh.2013.08.005 PMID: 24029726.

47. Meggs WJ, Dunn KA, Bloch RM, Goodman PE, Davidoff AL. Prevalence and nature of allergy and chemical sensitivity in a general population. Arch Environ Health. 1996; 51(4):75–82. https://doi.org/10.1080/000398996.1996.9936026 PMID: 8757407.

48. Johansson A, Bramarson A, Millqvist E, Nordin S, Bende M. Prevalence and risk factors for self-reported odour intolerance: the Skovde population-based study. Int Arch Occup Environ Health. 2005; 78(7):559–64. https://doi.org/10.1007/s00420-005-0616-8 PMID: 16001204

49. Eyeson-Annan M, Harvey L, Grant N, Baker D, Jorm L, Giffin M. The New South Wales Adult Health Survey 2002. 2003. Report No.: PH 030279.

50. Claesson AS, Palmquist E, Nordin S. Physical and chemical trigger factors in environmental intolerance. Int J Hyg Environ Health. 2018; 221(3):586–92. Epub 2018/03/11. https://doi.org/10.1016/j.ijheh.2018.02.009 PMID: 29523399.

51. Andersson MJ, Andersson L, Bende M, Millqvist E, Nordin S. The idiopathic environmental intolerance symptom inventory: development, evaluation, and application. J Occup Environ Med. 2009; 51(7):838–47. Epub 2009/06/23. https://doi.org/10.1097/JOM.0b013e31817f021 PMID: 19542897.

52. Soderholm A, Soderberg A, Nordin S. The experience of living with sensory hyperreactivity-accessibility, financial security, and social relationships. Health Care Women Int. 2011; 32(8):686–707. Epub 2011/07/20. https://doi.org/10.1007/s00420-011-0616-8 PMID: 21767095.

53. Karvala K, Sainio M, Palmquist E, Nyback MH, Nordin S. Prevalence of various environmental intolerances in a Swedish and Finnish general population. Environ Res. 2018; 161:220–8. Epub 2017/11/22. https://doi.org/10.1016/j.envres.2017.11.014 PMID: 29161654.

54. Baines CJ, McKeown-Eyssen GE, Riley N, Cole DE, Marshall L, Loescher B, et al. Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures. Occup Med (Lond). 2004; 54(6):408–18. Epub 2004/09/07. https://doi.org/10.1093/occmed/koq083 PMID: 15347780.

55. Dantoft TM, Elberling J, Brix S, Szczesi PB, Vesterhauge S, Skovbjerg S. An elevated pro-inflammatory cytokine profile in multiple chemical sensitivity. Psychoneuroendocrinology. 2014; 40:140–50. https://doi.org/10.1016/j.psyneuen.2013.11.012 PMID: 24485486.

56. Caress SM, Steinemann AC. A national population study of the prevalence of multiple chemical sensitivity. Arch Environ Health. 2004; 59(6):300–5. https://doi.org/10.3200/aeoh.58.6.300-305 PMID: 16238164.

57. McKeown-Eyssen G, Baines C, Cole DE, Riley N, Tyndale RF, Marshall L, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol. 2004; 33(5):971–8. Epub 2004/07/17. https://doi.org/10.1093/ije/dyh251 PMID: 15256524.
Multiple chemical sensitivity described in a general Danish population: The DanFunD study

58. Rask MT, Ombol E, Rosendal M, Fink P. Long-Term Outcome of Bodily Distress Syndrome in Primary Care: A Follow-Up Study on Health Care Costs, Work Disability, and Self-Rated Health. Psychosom Med. 2017; 79(3):345–57. https://doi.org/10.1097/PSY.0000000000000450 PMID: 27768649.

59. Jason LA, Taylor RR, Kennedy CL. Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms. Psychosom Med. 2000; 62(5):655–63. Epub 2000/10/06. https://doi.org/10.1097/00006842-200009000-00009 PMID: 11020095.

60. Hu H, Stern A, Rotnitzky A, Schlesinger L, Proctor S, Wolfe J. Development of a brief questionnaire for screening for multiple chemical sensitivity syndrome. Toxicol Ind Health. 1999; 15(6):582–8. Epub 1999/11/24. https://doi.org/10.1177/074823379901500606 PMID: 10560136.

61. Read D. Multiple Chemical Sensitivities. The Environmental Risk Management Authority—New Zealand. 2002.

62. Taylor JP, Kronid MM, Spidel M, Csima AC. Dietary adequacy of the rotary diversified diet as a treatment for “Environmental Illness”. Can J Diet Pract Res. 2002; 63(4):198–201. Epub 2002/12/21. https://doi.org/10.3148/63.4.2002.198 PMID: 12493142.

63. Aguilar-Aguilar E, Marcos-Pasero H, de la Iglesias R, Espinosa-Salinas I, Ramirez de Molina A, Reglero G, et al. Characteristics and determinants of dietary intake and physical activity in a group of patients with multiple chemical sensitivity. Endocrinol Diabetes Nutr. 2018; 65(10):564–70. Epub 2018/10/13. https://doi.org/10.1016/j.endinu.2018.07.009 PMID: 3039810.

64. Saito YA, Locke GR 3rd, Weaver AL, Zinsmeister AR, Tailey NJ. Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol. 2005; 100(12):2743–8. Epub 2006/01/06. https://doi.org/10.1111/j.1572-0241.2005.00288.x PMID: 16393229.

65. Batista ED, Andretta A, de Miranda RC, Nehring J, Dos Santos Paiva E, Schieferdecker ME. Food intake assessment and quality of life in women with fibromyalgia. Rev Bras Reumatol Engl Ed. 2016; 56(2):105–10. Epub 2016/06/09. https://doi.org/10.1016/j.rrbe.2015.08.015 PMID: 27267522.

66. Wiesmuller GA, Niggemann H, Weißbach W, Riley F, Maarouf Z, Dott W, et al. Sequence variations in ribosyltransferase-1 (RTH1) are not protective for multiple chemical sensitivities in German patients. J Toxicol Environ Health A. 2008; 71(11–12):786–94. Epub 2008/06/24. https://doi.org/10.1080/15287390801985620 PMID: 18569577.

67. Fujimori S, Hiura M, Yi CX, Xi L, Katoh T. Factors in genetic susceptibility in a chemical sensitive population using CEESI. Environ Health Prev Med. 2012; 17(5):357–63. Epub 2011/12/30. https://doi.org/10.1007/s12199-011-0260-8 PMID: 22205546.

68. Kaprio J, Sarna S, Koskenvuo M, Rantasalo I. The Finnish Twin Registry: formation and compilation, questionnaire study, zygosity determination procedures, and research program. Prog Clin Biol Res. 1978; 24 Pt B:179–84. Epub 1978/01/01. PMID: 569306.

69. Heinonen-Guzejev M, Koskenvuo M, Müssalo-Rauhamaa H, Vuorinen HS, Heikila K, Kaprio J. Noise sensitivity and multiple chemical sensitivity scales: properties in a population based epidemiological study. Noise Health. 2012; 14(60):215–23. Epub 2012/11/03. https://doi.org/10.1016/j.endinu.2015.08.015 PMID: 27267522.

70. Nordin M, Nordin S. Sleep and sleepiness in environmental intolerances: a population-based study. Sleep Med. 2016; 24:1–9. Epub 2016/11/05. https://doi.org/10.1016/j.sleep.2016.06.014 PMID: 27810173.

71. Castro-Marrero J, Zaragoza MC, Gonzalez-Garcia S, Aliste L, Saez-Francas N, Romero O, et al. Poor self-reported sleep quality and health-related quality of life in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Sleep Res. 2018; 27(6):e12703. Epub 2018/05/18. https://doi.org/10.1111/jsr.12703 PMID: 29770505.

72. Elsenbruch S, Harnish MJ, Orr WC. Subjective and objective sleep quality in irritable bowel syndrome. Am J Gastroenterol. 1999; 94(9):2447–52. Epub 1999/09/14. https://doi.org/10.1111/j.1572-0241.1999.001374.x PMID: 10484007.

73. Choy EH. The role of sleep in pain and fibromyalgia. Nat Rev Rheumatol. 2015; 11(9):513–20. Epub 2015/04/25. https://doi.org/10.1038/nrrheum.2015.56 PMID: 25907704.

74. Azuma K, Uchiyama I, Takano H, Tanigawa M, Azuma M, Bamba I, et al. Changes in cerebral blood flow during olfactory stimulation in patients with multiple chemical sensitivity: a multi-channel near-infrared spectroscopic study. PLoS One. 2013; 8(11):e80567. Epub 2013/11/28. https://doi.org/10.1371/journal.pone.0080567 PMID: 24278291.

75. Clark C, Paunovic K. WHO Environmental Noise Guidelines for the European Region: A Systematic Review on Environmental Noise and Cognition. Int J Environ Res Public Health. 2018; 15(2). Epub 2018/02/08. https://doi.org/10.3390/ijerph15020285 PMID: 29414890.

76. Clark C, Paunovic K. WHO Environmental Noise Guidelines for the European Region: A Systematic Review on Environmental Noise and Quality of Life, Wellbeing and Mental Health. Int J Environ...
77. Thuesen BH, Cerqueira C, Aadahl M, Ebstrup JF, Toft U, Thyssen JP, et al. Cohort Profile: the Health2006 cohort, research centre for prevention and health. Int J Epidemiol. 2014; 43(2):568–75. https://doi.org/10.1093/ije/dyt009 PMID: 23615486.